Skip to main content

Posters

March 02, 2019
Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This study examined the effect of baseline sleep quality on response to treatment with SHP465 mixed amphetamine salts (MAS) extended-release.
March 02, 2019
Background: Although stimulants are commonly used for attention-deficit/hyperactivity disorder (ADHD), 10–30% of patients have an inadequate response, adverse events, or comorbidities preventing use. There is a need for safe, effective nonstimulant options. Extended-release viloxazine (SPN-812) is…
March 02, 2019
Background: Age-adjusted cut-offs for two scales of ADHD-related at-home functional impairment, the Before School Functioning Questionnaire (BSFQ) and the Parent Rating of Evening and Morning Behavior Scale, Revised (PREMB-R), have recently been determined from a sample of U.S. youth (6–17y).
March 02, 2019
Background: Aggression is one of the most common reasons for psychiatric referral in children. The most prevalent subtype of maladaptive aggression is IA – which is reactive, overt, and occurs outside the social context. IA is a serious health concern, occurring across multiple neuropsychiatric…
March 02, 2019
BACKGROUND:Hyperammonemia and a carnitine deficiency with concomitant encephalopathy have been reported to result from valproate administration. The reported incidence of hyperammonemia in children treated with valproate is 19%. OBJECTIVE: This study explores the feasibility of reversing Valproate…
March 02, 2019
Background: In a pivotal, randomized, double-blind, placebo-controlled, phase 3 trial of children (6–12y) with ADHD (NCT02520388), treatment with HLD200, an evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH) significantly improved ADHD symptoms and reduced early morning…
March 02, 2019
Background: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) face significant disease burden. We evaluated disease burden in children/adolescents with ADHD and their caregivers from the caregiver’s perspective.
March 02, 2019
Background: Adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) face significant disease burden. This cross-sectional survey evaluated ADHD burden from the perspective of adolescents diagnosed with ADHD.
March 02, 2019
Objectives: To evaluate SHP465 mixed amphetamine salts (MAS) extended-release efficacy, safety, and tolerability by age group in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
March 02, 2019
Background: Executive function (EF) deficits are not generally considered synonymous with attention-deficit/hyperactivity disorder (ADHD). Evidence suggests stimulants improve ADHD symptoms and EF deficits in adults with ADHD, but the relationships between improvements in these domains after…
Back to Top